Jazz Pharmaceuticals to Report 2018 Fourth Quarter and Full Year Financial Results on February 26, 2019

Hamilton, Bermuda – 18 February 2019 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) whose Secured Loan Notes are listed on the BSX todayannounced that it will report its 2018 fourth quarter and full year financial results on Tuesday,February 26, 2019.  The full filing stated:

Jazz Pharmaceuticals to Report 2018 Fourth Quarter and Full Year Financial Results on February 26, 2019

DUBLIN, February 12, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) todayannounced that it will report its 2018 fourth quarter and full year financial results on Tuesday,February 26, 2019, after the close of the financial markets. Company management will host a liveaudio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT todiscuss fourth quarter and full year 2018 financial results and provide a business and financialupdate and guidance for 2019 financial results.

Interested parties may access the live audio webcast via the Investors section of the JazzPharmaceuticals website at http://www.jazzpharmaceuticals.com. Please connect to the websiteprior to the start of the conference call to ensure adequate time for any software downloads thatmay be necessary to listen to the webcast. A replay of the webcast will be archived on the websitefor at least one week.

Audio webcast/conference call:

U.S. Dial-In Number: +1 855 353 7924International Dial-In Number: +1 503 343 6056Passcode: 7095707

A replay of the conference call will be available through March 5, 2019 and accessible through oneof the following telephone numbers, using the passcode below:

Replay U.S. Dial-In Number: +1 855 859 2056

Replay International Dial-In Number: +1 404 537 3406

Passcode: 7095707

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated todeveloping life-changing medicines for people with limited or no options. As a leader in sleepmedicine and with a growing hematology/oncology portfolio, Jazz has a diverse portfolio ofproducts and product candidates in development, and is focused on transformingbiopharmaceutical discoveries into novel medicines. Jazz Pharmaceuticals markets Xyrem®(sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio®(defibrotide sodium) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S.and markets Erwinase®, Defitelio® (defibrotide) and Vyxeos® 44 mg/100 mg powder forconcentrate for solution for infusion in countries outside the U.S. For country-specific productinformation, please visit https://www.jazzpharma.com/medicines. For more information, please visitwww.jazzpharmaceuticals.com and follow us on Twitter at @JazzPharma.Jazz Pharmaceuticals Contacts:

Investors:

Kathee Littrell

Vice President, Investor RelationsIreland, +353 1 634 7887

U.S., +1 650 496 2717

Media:

Jacqueline Kirby

Vice President, Corporate Affairs & Government RelationsIreland, +353 1 697 2141

U.S., +1 215 867 4910